Evoke Pharma rises on new patent for nasal spray

Evoke Pharma

07/12/2022 19:26

(Updates)
    ** Shares of drugmaker Evoke Pharma Inc  EVOK.O  up 31.3% at
$1.95, among top pct gainers across U.S. stock exchanges
    ** Company says it has received patent for Gimoti, its nasal
spray product to treat moderate to severe gastroparesis
    ** Gastroparesis is a condition that affects the normal
muscle movements of stomach, causing persistent nausea and
vomiting
    ** Despite session's gain, stock down ~68% YTD
 (Reporting by Sriparna Roy)
 ((Sriparna.Roy@thomsonreuters.com))